AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05833165 — intervention group
Intervention type: BEHAVIORAL
Intervention: Feasibility of a supportive approach
Description: Evaluating reasons for patients to use the approach
Study NCT05048147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Mobilization
Description: The Community Mobilization (CM) strategy will include: (1) Community advisory board \[comprising local community-based organizations, government officials, and residents\], that will provide leadership support and buy-in for adoption of Clean Fuel- Clean- Stove (CF-CS) use; (2) Trained MoH community health extension workers, community health officers, community mobilizers and health education officers, who will form community action teams (CAT) to facilitate the implementation of CF-CS use via provision of support, knowledge exchange and performance feedback to the primary cooks in participating households; (3) Community dialogues with residents and households focused on shared concerns on the significance and importance of CF-CS use.
Study NCT06234293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near-infrared light device
Description: Nurses will have to find the vein for the PIVC using the near-infrared light device.
Study NCT05206084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System (IBS)
Description: Subjects in this arm will be treated with IBS
Study NCT05206084 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System
Description: Subjects in this arm will be treated with XIENCE
Study NCT06388733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Participants will receive niraparib 200 mg orally once daily starting on Day 1 of RT. Following completion of RT, participants will continue niraparib adjuvant therapy orally once daily on Days 1 to 28 of each 28-day cycle until progression by BICR
Study NCT06388733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Participants randomized to the comparator arm (Arm B) will receive SOC TMZ 75 mg/m2 orally once daily with RT starting on Day 1 of RT. Following completion of RT, participants will complete a 4-week rest period, and then receive adjuvant TMZ 150 to 200 mg/m2 orally once daily on Days 1 to 5 of each 28-day cycle until progression by BICR or for a maximum of 6 cycles.
Study NCT06539052 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anti-HDV positive with the reflex testing methodology
Description: Rate of screening for HBsAg in all migrants attending to one of the center participating to the project rate of screening for anti-Delta in all HBsAg patients identified rate of anti-Delta-positivity in HBsAg-positive subjects rate of linkage-to-care at one of the infectious disease center participating to the project rate of HDV-RNA testing in all anti-Delta positive subjects rate of treatment for HDV in all HDV-RNA-positive subjects Rate of screening for HIV Ab in all migrants attending to one of the center participating to the project Rate of screening for HCV Ab in all migrants attending to one of the center participating to the project.
Study NCT05672849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Surgical Instruments/Devices (Sheaths and Irrigator)
Description: Patients who choose to undergo fetoscopic surgery will be offered participation in this study. All patients will undergo a fetoscopic repair of the fetal open neural tube defect with the use of the modified devices in this study.
Study NCT04907370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1
Study NCT05252962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptides
Description: Collagen peptides will be orally administered and pharmacokinetic parameters will be assessed up to 6 hours after study product intake.
Study NCT04907370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: 1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC.~2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT.~3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1
Study NCT04907370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
Study NCT04907370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
Study NCT04907370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (80mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
Study NCT04907370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (80mg/m2)
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
Study NCT04907370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (100mg/m2)
Description: Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Study NCT04907370 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
Study NCT04907370 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
Study NCT06362265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3209590
Description: Administered SC.
Study NCT05844566 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Decision Support System (DSS)
Description: This DSS will provide estimates of potential benefits in terms of ASCVD risk reduction (composite endpoint: combined non-fatal myocardial infarction, non-fatal ischaemic stroke and cardiovascular death) as a function of treatment duration and magnitude of LDL-C lowering.~The DSS does not recommend treatments but shows the expected ASCVD risk, absolute and relative ASCDV risk reductions and number needed to treat for the various treatments selected by the clinical user on the potential value of initiation of an add-on therapy for reducing the risk of recurrent Cardiovascular (CV) events. Implementing the patient-specific recommendation remains at the clinicians' discretion.
Study NCT05606406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nocturnal Oxygen
Description: Nocturnal oxygen will be increased hourly for a period of four hours up to 4 liters per minute (LPM). If the oxygen saturation (SpO2) falls below 70% the oxygen rate will be increased until patients achieve the threshold of 70% and then will proceed with titrations of 1 liter per minute LPM per hour.
Study NCT04385940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ddrops® products, 50,000 IU, Oral
Description: Vitamin D3
Study NCT04385940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 1000IU
Study NCT06502158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200 milligrams (mg)
Study NCT06502158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 600 micrograms (ug)
Study NCT05969704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI fusion targeted prostatic biopsy
Description: combines the pictures from an MRI and an ultrasound to create a detailed 3-D image of the prostate. This procedure makes it easier to see an abnormal lesion of prostate in order to guide the biopsy needle into the abnormal lesion
Study NCT05969704 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI cognitive targeted prostatic biopsy
Description: the biopsy operator reviews the MR images and creates a mental three-dimensional representation of the prostate and of the lesion within it to take a biopsy from the lesion
Study NCT06338995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3650150
Description: Administered SC.
Study NCT06338995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.
Study NCT06338995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray.
Study NCT06338995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray.
Study NCT06269913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeSC
Description: Iron/yeast complex
Study NCT06788665 — intervention group
Intervention type: DEVICE
Intervention: Medical Device Dermalyser
Description: Dermalyser is an Artificial Intelligence (AI) application (app) that allows medical professionals to take pictures of cutaneous lesions with the help of a smartphone camera. A dermatoscope is connected to the smartphone camera and is used to take the digital image of cutaneous lesions with suspicion of melanoma. Based on image processing algorithms, the app does a detailed analysis of the captured cutaneous lesion. In this clinical investigation, the objective is to test the device performance in a prospective setting in patients with a suspicion of primary cutaneous melanoma, to validate the added AI component. The intended purpose of the device is not to replace the physician's assessment, but rather to assist physicians in their assessment. Consequently, the final device should be regarded as a second opinion to augment clinical decision-making. The ultimate aim is to develop a tool that may augment clinical decision-making.
Study NCT06788574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECAR device: MCRR. The sign producer is an INDIBA® 448 kHz RF device that has a vaginal/ or rectum electrode (made in Barcelona, Spain)
Description: TECAR (Transfer Electrical, Capacitive, and Resistive) is originally used in Italy. TECAR therapy is a radiofrequency (RF) therapy, which produces high-frequency waves. RF can be capacitive or resistive The capacitive mode (CET) generates energy in electrolyte-rich soft tissues such as muscles and vascular or lymphatic tissues . The resistive mode (RET) directs energy to deeper tissues that contain more fat and fibers (such as bones, ligaments, and tendons;
Study NCT06788574 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: pelvic floor exercises
Description: pelvic floor exercise will be performed with the perineometer twice a week for eight weeks (16 sessions), with five sets of 20 repetitions each
Study NCT06788574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pelvic floor exercises
Description: pelvic floor exercise will be performed with the perineometer twice a week for eight weeks (16 sessions), with five sets of 20 repetitions each
Study NCT06788574 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: sham treatment by Tecar device for 15 min without producing any waves.
Study NCT06788548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: combined endoscopic-laparoscopic sentinel lymph node navigation surgery
Description: 1. Determination of tumor location and sentinel lymph node: endoscopic staining (2mg indocyanine green, four-quadrant submucosal injection) was used to determine the location of the lesion during laparoscopic surgery combined with endoscopic localization to ensure effective and safe resection margins. The staining technique was used to identify the sentinel lymph nodes basin, and en bloc resection of the lymph node basin biopsy was performed.~2. Standard of lymph node basin dissection: All sentinel nodes are located within the lymphatic basin, which is considered the primary lymphatic drainage area for each patient. Follow the SENORITA trail criteria\[9\], lymphatic basin is delineated by the distribution of dye within the lymphatic channels, as seen in dye mapping. The proximal extent of the lymphatic basin is demarcated by the fatty tissue adjacent to the stomach wall, while the distal boundary is marked by the most distant stained node from the stomach.
Study NCT06788548 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic D2 radical gastrectomy
Description: Preparation: The patient is positioned supine with general anesthesia. An orogastric tube and Foley catheter are inserted. Antibiotics are administered, and sequential stockings are applied. Port Placement: Pneumoperitoneum is created via a Veress needle at the umbilicus. Working ports are placed in the upper quadrants, with a fifth port for liver retraction. Abdominal Exploration: The abdomen is inspected for metastases, and peritoneal cytology is performed. Dissection and Lymph Node Removal: The lesser omentum is divided near the liver, reaching the cardia and diaphragm. The gastrocolic ligament is divided along the transverse colon. Lymph node dissection begins along the splenic artery, then proceeds to the left gastric artery and celiac nodes. The left gastric vessels are controlled with endoclips.After lymph node dissection, distal subtotal gastrectomy is performed. Digestive tract reconstruction is typically done through a mini-laparotomy.
Study NCT05898607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous Erector spinae plane block
Description: continuous U/S-Guided ESPB of 5 ml/hr of 0.125% bupivacaine started through the catheter before the surgical procedure
Study NCT06458335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Perceived Social Isolation
Description: 6 sessions focused on addressing thoughts, emotions, and behaviors that maintain feeling alone as a way to reduce loneliness and substance use
Study NCT06458335 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education provides information on the importance and benefits of and guidelines for living a health lifestyle
Study NCT06785337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled nitroglycerin
Description: Inhaled nitroglycerin
Study NCT06788197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811+fulvestrant
Description: Cohort A will receive treatment with SHR-A1811 and fulvestrant
Study NCT06788197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811 +Fulvestrant +HS-10352
Description: Cohort B will receive treatment with SHR-A1811+Fulvestrant+HS-10352
Study NCT05083416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Nightly Fasting
Description: Limiting daily period of food intake to 10 hours and nightly fasting period to 14 hours.
Study NCT05083416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular Eating pattern
Description: Food intake not limited to a specific time during day/night.
Study NCT06788977 — intervention group
Intervention type: DEVICE
Intervention: external Trigeminal Nerve Stimulation
Description: External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine.~The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes.
Study NCT06789133 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF exercises and Body weight supported treadmill gait training
Description: PNF Exercises:~.Proprioceptive neuromuscular facilitation exercises include D1 Flexion and D1 Extension of lower limb ,D2 flexion D2 extension of lower limb .rhythmic initiation ,hold relax ,pelvic pattern and contract relax technique . subjects will perform each exercise for 30sec with resting interval of 30 to 60 seconds Will be provided after completion of each exercise. 3 sessions will be held per week, For 8 weeks~Gait training:~Body weight supported treadmill gait training for 20 minutes 3 sessions per week.~In total all PNF exercises with gait training will be held for 40-45 minutes.
Study NCT06789133 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body weight supported treadmill gait training and Routine physical therapy
Description: Body Weight Supported Treadmill Training (BWSTT):~This will include body weight supported treadmill gait training. 10 % BWSTT or 20% BWSTT. The session will of 20 minutes .3 sessions will be Held per week.~Routine physical therapy:~Stretching and strengthening of lower extremities In total all BWSTT along with routine physical therapy protocol will be held for 40-45minutes .3 sessions will be held per week.
Study NCT05806697 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electroencephalogram (EEG)
Description: The EEG will be uniquely performed during for the whole study if a given subject converts to symptomatic AD or in the occurrence of significant cognitive decline.
Study NCT05806697 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Oculomotor tests
Description: All participants in the INSIGHT-2 study are invited to perform the oculomotor test, excepting subjects reporting oculomotor disorders.
Study NCT05806697 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: All INSIGHT-2 participants will undergo a baseline MRI (structural and resting state fMRI) a follow-up MRI at M12, M36 and M60.
Study NCT05806697 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 18-F amyloid PET Scan
Description: The primary endpoint is conversion to the symptomatic stage in subjects at risk, identified by positive amyloid staining (A+) on florbetapir PET imaging. Participants will receive an injection of 18F-Florbetapir prior to undergoing amyloid PET scanning. Florbetapir (18F) is an experimental imaging compound labeled with \[18F\] fluorine that decays by positron (β+) emission and has a half-life of 109.77 min. This procedure will be done at baseline.
Study NCT05806697 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 18F-fluorodeoxyglucose (FDG) PET Scan
Description: Participants will receive an injection of Fludeoxyglucose 18F prior to undergoing FDG-PET. The \[18F\]FDG is the most well-known radiopharmaceutical positron emitter, in both clinical and preclinical fields.
Study NCT05806697 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood sampling
Description: A total of 80 ml of whole blood will be collected for each participant in the INSIGHT-2 study for routine laboratory assessment and biobank sampling.
Study NCT05806697 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Lumbar puncture
Description: A lumbar puncture for cerebrospinal fluid (CSF) collection is proposed to all participants.
Study NCT05918328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel+trastuzumab+pyrrolitinib
Description: Albumin paclitaxel 260mg/m 2+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+pyrrolitinib (320mg, QD), one cycle every 21 days.
Study NCT05918328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel+Carboplatin+trastuzumab+Parstuzumab
Description: Docetaxel 75 mg/m2+carboplatin (AUC=6)+trastuzumab (initial loading dose 8 mg/kg, sequential maintenance dose 6 mg/kg)+patuzumab (initial loading dose 840mg, sequential maintenance dose 420 mg), one cycle every 21 days
Study NCT04389372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Mindfulness by smartphone combined to video calls for clinical evaluation in patients with chronic migraine and medication overuse after withdrawal program
Study NCT06358469 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Re-excision of vulvar cancer margin
Study NCT06358469 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Surveillance
Description: The investigator will follow the patient to watch for side effects and keep track of patient's health
Study NCT04988074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel
Study NCT06263959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GST-HG131
Description: GST-HG131 will be administered.
Study NCT06263959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match GST-HG131
Description: Placebo to match GST-HG131 will be administered.
Study NCT06169605 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: removal of primary tumor, neck dissection
Description: removal of the primary tumor with safety margins and removal of the neck lymph node levels I, II, III and IV. histological assessment of tumor thickness and whether it is associated with positive nodes in level IV or not.
Study NCT05645003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency real-time rTMS protocol
Description: It was planned to apply a total of 1200 beats to the dorsolateral prefrontal cortex daily for 15 sessions. Along with the daily rTMS session, patients will continue to use the drugs in the medical treatment (pregabalin, gabapentin, carbamazepine) at the same effective dose. No dose changes will be made during rTMS sessions.